Pandrug-Resistant<i>Acinetobacter baumannii</i>Causing Nosocomial Infections in a University Hospital, Taiwan

Hsueh, Po‐Ren; Teng, Lee-Jene; Chen, Cheng-Yi; Chen, Wen-Hwei; Ho, Shen‐Wu; Luh, Kwen‐Tay

doi:10.3201/eid0808.020014

Cited by 55 publications

(62 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The susceptibility of E. coli, K. pneumoniae and Proteus mirabilis isolates with ESBL-producing phenotypes were determined using the disk diffusion method recommended by the CLSI [12]. MDR isolates were defined as those resistant to all of the following antimicrobial agents: ceftazidime; piperacillin/tazobactam; cefepime; ciprofloxacin; levofloxacin; imipenem; meropenem; gentamicin; and amikacin [13,14]. CR isolates were defined as those resistant to imipenem and meropenem.…”

Section: Bacterial Culture and Susceptibility Testingmentioning

confidence: 99%

Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance study

Kuo¹,

Yu²,

Kuo³

et al. 2008

International Journal of Antimicrobial Agents

Self Cite

View full text Add to dashboard Cite

Section: Bacterial Culture and Susceptibility Testingmentioning

confidence: 99%

Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance study

Kuo¹,

Yu²,

Kuo³

et al. 2008

International Journal of Antimicrobial Agents

Self Cite

View full text Add to dashboard Cite

“…1 the most important species from this genus is Acinetobacter baumannii which has emerged in recent years as a major cause of healthcare-associated infection (HAI) and are responsible for serious nosocomial infections especially in intensive care units. 2,3 this bacteria present a challenge to Infection Control Department at hospitals since it can be found anywhere in the hospital environment with ability to survive for prolonged periods thus potentiating its ability for nosocomial spread. 4 Similarly, A. baumannii infections present a challenge to clinicians since the organism can rapidly acquire antimicrobial resistance.…”

Section: Introductionmentioning

confidence: 99%

Acinetobacter baumannii bloodstream infections in a tertiary hospital: Antimicrobial resistance surveillance

Al-Mously¹

2013

Int. j. infect. control

View full text Add to dashboard Cite

Nosocomial bacteremia caused by Acinetobacter baumannii is of increasing concern in critically ill patients. there is a world-wide increase in the emergence of multidrug-resistant (MDR) A. baumannii to antimicrobials. therefore we conducted this study to evaluate the resistance pattern of A. baumannii in patients with bacteremia. this is a retrospective study conducted in a tertiary hospital in Saudi Arabia. During the period from April 2006 till April 2010, data for A. baumannii isolated from blood were collected. Multidrug resistant A. baumannii was defined as resistance to three or more classes of antibiotics.We found 191 isolates of A. baumannii from blood. the majority of cases were reported in surgical ICU (40.8%). the highest resistance rates to antimicrobials were reported for cefepime (73.8%) and piperacillin / tazobactam (72.3%), followed by ciprofloxacin (68%), and gentamicin (66%). Resistance rates were also high to imipenem (61.3%) and meropenem (60.7%). low rates of resistance to colistin (0.5%) and to tigecycline (3.9%) were observed. MDR was observed in 132 (69%) of the A. baumannii isolates and 104 (78.8%) of these MDR strains showed sensitivity only to colistin and tigecycline.Bacteremia due to A. baumannii was the highest in surgical ICU. the emergence of MDR A. baumannii is increasing and the resistance rates to carbapenems are alarming. Urgent measures are in need to slow the development of MDR AB. We recommend encouraging clinicians for strict adherence to infection control Corresponding Author

show abstract

“…Acinetobacter species, especially Acinetobacter baumannii, have been shown to be associated with serious nosocomial infections in critically ill patients in intensive care units for several years. These microorganisms have developed resistance to several classes of antimicrobial agents, resulting in the dangerous situation of physicians having only a few, or even sometimes no, effective antibiotics for the treatment of infections caused by MDR A. baumannii (3,4). Sulbactam, a ␤-lactamase inhibitor, has a major role in irreversible binding to block the activity of ␤-lactamase produced by bacteria against ␤-lactam antibiotics, and in particular, this agent has intrinsic activity against Acinetobacter spp.…”

mentioning

confidence: 99%

Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii

Jaruratanasirikul

Wongpoowarak

Wattanavijitkul

et al. 2016

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Sulbactam is being considered as an alternative concomitant medication with other effective antibiotics for the treatment of multidrug-resistant (MDR) Acinetobacter baumannii infections. Pathophysiological changes in critically ill patients with severe sepsis, resulting in altered pharmacokinetic (PK) patterns for antibiotics, are important factors in determining therapeutic success. The aims of this study were (i) to examine the population PK parameters and (ii) to assess the probability of target attainment (PTA) for sulbactam in patients with severe sepsis caused by A. baumannii. PK studies were carried out following administration of 2 g of sulbactam every 12 h on the 4th day of drug administration in 27 patients, and a Monte Carlo simulation was performed to determine the PTA of achieving 40% exposure time during which the plasma drug concentration remained above the MIC (T >MIC ) and 60% T >MIC . The central and peripheral volumes of distribution were 14.56 and 9.55 liters, respectively, and total clearances of sulbactam were 2.26 liters/h and 7.64 liters/h in patients aged >65 years and <65 years, respectively. The high PTAs (>90%) for targets of 40% T >MIC and 60% T >MIC with a MIC of 4 g/ml were observed when sulbactam was administered by a 4-h infusion of 1 g every 12 h and 1 g every 8 h, respectively. Sulbactam would be an alternative antibiotic option to coadminister with colistin for the treatment of infections caused by MDR A. baumannii. However, for pathogens with MICs of >4 g/ml, higher dosage regimens of sulbactam are required.

show abstract

Pandrug-ResistantAcinetobacter baumanniiCausing Nosocomial Infections in a University Hospital, Taiwan

Cited by 55 publications

References 25 publications

Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance study

Antimicrobial resistance of bacterial isolates from respiratory care wards in Taiwan: a horizontal surveillance study

Acinetobacter baumannii bloodstream infections in a tertiary hospital: Antimicrobial resistance surveillance

Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii

Contact Info

Product

Resources

About